MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds, net of issuance
costs, from issuing...
$5,567K
Net cash provided by
(used) in financing...
$5,526K
Canceled cashflow
$41K
Net increase
(decrease) in cash and cash...
$1,138K
Canceled cashflow
$4,388K
Payment of preferred
stock dividend
$41K
Deconsolidation of subsidiary
$4,947K
Stock-based compensation
$1,673K
Prepaid expenses and
other assets
-$1,544K
Changes in lease
liability
$10K
Depreciation
$1K
Net cash used in
operating activities
-$4,303K
Effect of exchange rate
changes on cash and cash...
-$85K
Canceled cashflow
$8,175K
Accounts payable,
accrued and other...
-$11,079K
Net loss
-$1,399K
Back
Back
Cash Flow
source: myfinsight.com
Cyclacel Pharmaceuticals, Inc. (CYCC)
Cyclacel Pharmaceuticals, Inc. (CYCC)